Combined PD-1/LAG-3 blockade further delayed tumor growth when compared with IC mAbs (P = 0.0001) or monotherapy with anti-LAG-3 (P = 0.0201) or anti-PD-1 (P = 0.5257) mAbs. Here, LAG3 is linked to neoplasm.